# Traffic Light Medication Checker for 12-Month Prescriptions

**Quick visual guide for in-consultation decision-making**

**Updated February 2026**

---

## How to Use This Tool

1. **Check medication zone** - GREEN (usually OK), AMBER (needs assessment), RED (not suitable)
2. **For AMBER medications** - Use Quick Screening Table first, then detailed guidance if needed
3. **Make decision** - Green = usually OK for 12mo, Amber = check criteria, Red = NO

---

---

## üü¢ GREEN ZONE: Generally Suitable for 12 Months

**If patient stable, these medications can be prescribed for 12 months**

| Medication | Annual Monitoring Required | Notes |
|------------|---------------------------|-------|
| **Statins** (atorvastatin, simvastatin, rosuvastatin) | Lipids annually | LFTs NOT routinely required (BPAC) |
| **Calcium channel blockers** (amlodipine, felodipine) | BP annually | - |
| **Beta blockers** (metoprolol, bisoprolol, atenolol) | BP, HR annually | Watch for symptomatic bradycardia |
| **ICS** (fluticasone, budesonide) | Spirometry if available, technique check | - |
| **LABA/ICS combos** (Seretide, Symbicort) | Spirometry if available, technique check | - |
| **LAMA** (tiotropium) | Spirometry if available | No SA renewal needed (Dec 2025 change) |
| **Levothyroxine** | TSH annually (once stable) | If dose stable 6+ months |
| **Oral contraceptives** | BP annually | Can dispense 6-month intervals |
| **PPIs** (omeprazole, esomeprazole) | Usually none | Review need annually |
| **Aspirin** (antiplatelet dose) | Annual bleeding risk assessment | - |
| **Clopidogrel, Ticagrelor** | Annual bleeding risk assessment | Usually post-ACS, specialist-initiated |
| **SSRIs/SNRIs** (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, venlafaxine) | **Annual review + discussion about duration** | **See CRITICAL CAVEATS below** |
| **Mirtazapine** | Annual review + discussion about duration | Monitor weight |
| **Lamotrigine** (mood stabilizer) | Annual review | - |
| **Levetiracetam** (epilepsy) | Annual review | - |
| **Buspirone** (anxiolytic) | Annual review | - |
| **Hydroxyzine** (anxiolytic) | Annual review | Sedation, anticholinergic effects in elderly |
| **Atomoxetine** (ADHD, non-stimulant) | Annual review + BP monitoring | Monitor BP, cardiovascular effects |
| **DPP-4 inhibitors** (vildagliptin, sitagliptin) | Annual review | No hypo risk as monotherapy |
| **Theophylline** (oral sustained-release) | **Drug levels + annual review** | Narrow therapeutic window, check levels 6-monthly |
| **Montelukast** | Annual review | - |
| **Dementia medications** (donepezil, rivastigmine, memantine) | Annual review | Usually specialist-initiated |
| **Levodopa preparations** (co-careldopa, co-beneldopa) | Annual review | Usually specialist-managed |
| **Calcium + Vitamin D** | Annual review | - |

**CRITICAL CAVEATS for SSRIs/SNRIs:**

**When NOT suitable for 12 months:**
- ‚ùå Recently started (<6 months)
- ‚ùå Recent dose change (<3 months)
- ‚ùå Age <18 years (close monitoring required)
- ‚ùå High discontinuation risk if doses missed

**üü° PROFESSIONAL GUIDANCE:**
- **Annual discussion** about treatment duration is **MANDATORY** (BPAC/RNZCGP audit requirement)
- Continue minimum 6-12 months after remission before considering withdrawal
- Document discussion about ongoing need annually

**Specific risks to monitor:**
- **Hyponatraemia** (especially elderly, first 4 weeks - sertraline/escitalopram highest risk)
- **Falls risk** (especially elderly)
- **Fracture risk** (long-term use)
- **Venlafaxine:** Monitor BP at doses >150mg/day

**ACTION REQUIRED for SSRIs/SNRIs:**
- ‚úì Confirm stable on current dose 6+ months
- ‚úì Annual review MUST include discussion of ongoing need
- ‚úì Patient understands to contact if suicidal thoughts or worsening symptoms
- ‚úì Elderly: monitor for hyponatraemia symptoms (confusion, falls, nausea)

**SOURCE:** BPAC depression management guidance (2017, 2021); RNZCGP SSRI audit

---

**ACTION REQUIRED (all GREEN zone):**
- ‚úì Confirm patient stable on current dose 6+ months
- ‚úì Annual review appointment booked
- ‚úì Patient understands to contact if symptoms change

---
---

## üü° AMBER ZONE: Quick Screening Table

**Use this table for FAST screening - detailed guidance follows below**

| Medication Class | Key Parameter | 12mo OK if: | MAX if: | Monitoring |
|-----------------|---------------|-------------|---------|------------|
| **ACEi/ARBs** | **eGFR** | ‚â•60 | <45 = 6mo max | 6-12 monthly renal + K+ |
| **Metformin** | **eGFR** | >45 | <30 = STOP | 6-12 monthly renal |
| **DOACs** | **CrCl (Cockcroft-Gault)** | Varies by drug | See table below | 6-12 monthly CrCl |
| **Spironolactone** | **K+, eGFR** | NEVER 12mo | 6mo max always | 1wk, 1mo, then 6-monthly |
| **TCAs** | **Age, cardiac risk** | Use judgment | 6mo safer | Annual + ECG if indicated |
| **Diuretics (loop)** | **Electrolytes** | Rarely | 6mo max | 3-6 monthly electrolytes |
| **Diuretics (thiazide)** | **Electrolytes** | 6-12mo | - | 6-monthly electrolytes |
| **NSAIDs (Rx)** | **Renal, triple whammy** | 6-12mo if alone | 3mo if triple whammy | 3-6 monthly if chronic |
| **Allopurinol** | **eGFR** | >60 | <30 = 6mo, dose reduce | 6-12 monthly renal |
| **Colchicine** | **eGFR** | >60 | <30 = 3mo, dose reduce | 6-12 monthly renal |
| **SGLT-2i (empagliflozin)** | **eGFR** | >30 | <20 = STOP | Annually (+ sick day rules) |
| **Sulfonylureas** | **Age, renal** | If <70 & eGFR >60 | Age>70 or eGFR<60 = 6mo | Monitor for hypos |
| **GLP-1 agonists** | **Injectable** | Yes (weekly injection) | - | Annual review |
| **Gabapentin/Pregabalin** | **eGFR, addiction risk** | eGFR >60 | <30 = 6mo, dose reduce | 6-12 monthly renal |
| **Oral steroids (chronic)** | **Multiple** | NEVER 12mo | 3-6mo max | Multiple - see detail |
| **Bisphosphonates** | **eGFR, dental** | eGFR >35 | <35 = specialist | Annual renal + dental check |

**DOAC Details:**
- **Dabigatran:** CrCl ‚â•50 = 12mo OK; CrCl 30-49 = 6mo max; CrCl <30 = CONTRAINDICATED
- **Rivaroxaban:** CrCl ‚â•50 = 12mo OK; CrCl 30-49 = 6mo (dose reduce); CrCl 15-29 = 3mo (dose reduce)
## üü° AMBER ZONE: Individual Assessment Required - DETAILED GUIDANCE

**These medications CAN be prescribed for 12 months in SELECTED patients - check criteria first**

### ACE Inhibitors / ARBs
*(enalapril, lisinopril, quinapril, irbesartan, losartan)*

| eGFR | Prescription Duration | Monitoring Frequency | Action Required |
|------|----------------------|---------------------|-----------------|
| **‚â•60** | **12 months OK** | Annually | Renal function + K+ annually |
| **45-59** | **6-12 months** (GP discretion) | 6-monthly | Renal function + K+ 6-monthly |
| **30-44** | **MAX 6 months** | 4-6 monthly | Renal function + K+ 4-6 monthly |
| **<30** | **MAX 3-6 months** | 3-4 monthly | Specialist input may be needed |

**CRITICAL CHECKS:**
- ‚òê Check eGFR and K+ BEFORE decision
- ‚òê eGFR stable (not declining >15% in 3 months)?
- ‚òê K+ <5.0 mmol/L?
- ‚òê NOT on "triple whammy" (ACEi + diuretic + NSAID)?
- ‚òê After initiation/dose change: recheck renal function + K+ at 5-10 days

**If YES to all ‚Üí can use 12 months if eGFR ‚â•60**  
**If eGFR 45-59 ‚Üí use clinical judgment (6 or 12 months)**  
**If eGFR <45 ‚Üí MAX 6 months**

---

### Metformin

| eGFR | Prescription Duration | Monitoring Frequency | Dose Limit |
|------|----------------------|---------------------|-----------|
| **>60** | **12 months OK** | Annually | 3g/day max |
| **45-60** | **12 months OK** | Annually | 2g/day max |
| **30-44** | **MAX 6 months** | 6-monthly | 1g/day max (off-label, KDIGO supports 2g if >45) |
| **15-29** | **MAX 3 months** | 3-monthly | Specialist advice |
| **<15** | **CONTRAINDICATED** | - | STOP metformin |

**CRITICAL CHECKS:**
- ‚òê Check eGFR BEFORE decision
- ‚òê Patient NOT acutely unwell / dehydrated?
- ‚òê NOT planning IV contrast within next 3 months?
- ‚òê If eGFR 30-44: dose appropriate for renal function?

**ACTION REQUIRED:**
- eGFR >45: Annual renal function monitoring ‚Üí **12 months OK**
- eGFR 30-45: 6-monthly renal function monitoring ‚Üí **MAX 6 months**
- Elderly/frail: Consider 6 months even if eGFR >45

---

### DOACs (Dabigatran, Rivaroxaban, Apixaban)

| DOAC | Renal Threshold | Prescription Duration | Monitoring Frequency |
|------|----------------|----------------------|---------------------|
| **Dabigatran** | CrCl ‚â•50 | **12 months OK** | 6-12 monthly CrCl |
| | CrCl 30-50 | **MAX 6 months** (dose reduce) | 6-monthly CrCl |
| | CrCl <30 | **CONTRAINDICATED** | - |
| **Rivaroxaban** | CrCl ‚â•50 | **12 months OK** | 6-12 monthly CrCl |
| | CrCl 30-49 | **MAX 6 months** (dose reduce) | 6-monthly CrCl |
| | CrCl 15-29 | **MAX 3 months** (dose reduce) | 3-monthly CrCl |
| | CrCl <15 | **AVOID** | - |
| **Apixaban** | CrCl ‚â•50 | **12 months OK** | 6-12 monthly CrCl |
| | CrCl 30-49 | **6-12 months** | 6-monthly CrCl |
| | CrCl 15-29 | **MAX 6 months** (dose reduce for AF) | 3-monthly CrCl |
| | CrCl <15 | **AVOID** | - |

**CRITICAL CHECKS:**
- ‚òê Calculate **CrCl using Cockcroft-Gault** (NOT eGFR) - trials used this
- ‚òê Age >75 years? ‚Üí Higher bleeding risk, consider 6 months
- ‚òê Falls risk / previous bleeds? ‚Üí Consider 6 months
- ‚òê On antiplatelet (aspirin/clopidogrel)? ‚Üí Consider 6 months
- ‚òê Renal function declining? ‚Üí Shorter duration

**ACTION REQUIRED:**
- CrCl >60: Use "CrCl/10 rule" ‚Üí if CrCl 80, check every 8 months, round to **6-12 monthly**
- CrCl <60: **6-monthly** CrCl monitoring minimum
- Dabigatran most renally excreted (80%) ‚Üí lowest threshold for exclusion

**Calculator:** https://nzf.org.nz (Cockcroft-Gault)

---

### Spironolactone

| eGFR | K+ | Prescription Duration | Monitoring |
|------|----|-----------------------|-----------|
| **>30** | **<5.0** | **MAX 6 months** | Renal + K+ at 1 week, 1 month, then 6-monthly |
| **<30** | - | **CONTRAINDICATED** | - |
| - | **‚â•5.0** | **CONTRAINDICATED** | - |

**CRITICAL:** This is NOT a 12-month drug even when stable
- Heart failure patients need closer monitoring
- Risk of hyperkalaemia increases with declining renal function

---

### Tricyclic Antidepressants (TCAs)

| Medication | Suitable for 12mo? | Why AMBER not GREEN | Monitoring |
|------------|-------------------|---------------------|------------|
| **Amitriptyline, Nortriptyline, Doxepin, Clomipramine** | **Use clinical judgment - usually 6 months safer** | Cardiac risk, overdose risk, anticholinergic effects | ECG if cardiac risk factors, annual review |

**üü° AMBER ZONE Considerations:**
- **Cardiotoxic** (QT prolongation)
- **Dangerous in overdose** (intentional or accidental)
- **Anticholinergic effects** (confusion, urinary retention, especially elderly)

**When to use 6 months instead of 12:**
- Elderly patients (higher falls risk, confusion risk)
- Cardiac disease or risk factors
- Suicide/overdose risk
- Cognitive impairment

**ACTION REQUIRED:**
- Consider ECG before initiating if cardiac risk factors
- More frequent reviews if high-risk patient
- **6 months usually safer than 12 months** for TCAs

**NOTE:** TCAs less commonly prescribed now; SSRIs preferred first-line  
**SOURCE:** BPAC depression management guidance

---

### Diuretics (Thiazides and Loop)

| Type | Prescription Duration | Monitoring | Notes |
|------|----------------------|-----------|-------|
| **Thiazides** (bendroflumethiazide, indapamide) | **6-12 months** | Electrolytes + renal function 6-monthly | Initially closer monitoring, then 6-12 monthly once stable |
| **Loop diuretics** (furosemide, bumetanide) | **MAX 6 months** | Electrolytes + renal function 3-6 monthly | Especially in heart failure, more frequent monitoring |

**CRITICAL CHECKS:**
- ‚òê Check electrolytes (Na+, K+) and renal function regularly
- ‚òê If on ACEi/ARB + diuretic ‚Üí warn about "triple whammy" with NSAIDs
- ‚òê Heart failure patients ‚Üí closer monitoring
- ‚òê Elderly ‚Üí higher risk of electrolyte imbalance

---

### NSAIDs (Prescription Strength)
*(Naproxen, diclofenac, meloxicam, celecoxib)*

| Situation | Prescription Duration | Monitoring | Risk Level |
|-----------|----------------------|-----------|------------|
| **Alone, young, normal renal function** | **6-12 months** (if chronic use unavoidable) | 6-monthly renal function + BP | Low risk |
| **With ACEi/ARB ("double whammy")** | **MAX 6 months** | 3-6 monthly renal function + K+ | Moderate risk |
| **With ACEi/ARB + diuretic ("triple whammy")** | **MAX 3 months** | Monthly renal function initially, then 3-monthly | **HIGH RISK** |
| **eGFR <60** | **MAX 3-6 months** | 3-monthly renal function | High risk |
| **Age >65** | **MAX 6 months** | 6-monthly monitoring | GI bleed risk |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è NSAIDs ideally should be **SHORT-TERM only** (days to weeks)
- ‚ö†Ô∏è If chronic use unavoidable, consider alternatives: paracetamol ¬± codeine, topical NSAIDs
- ‚ö†Ô∏è **"Triple whammy" = NSAID + ACEi/ARB + diuretic** ‚Üí 30% increased AKI risk
- ‚ö†Ô∏è Number needed to harm = 158 for triple whammy over 1 year

**ACTION REQUIRED:**
- Check renal function + electrolytes BEFORE prescribing
- If on ACEi/ARB: warn patient about over-the-counter NSAIDs
- Consider gastroprotection (PPI) if long-term use needed
- First 30 days = highest AKI risk

**SOURCE:** BPAC triple whammy guidance (2018)

---

### Allopurinol

| eGFR | Prescription Duration | Dose Adjustment | Monitoring |
|------|----------------------|----------------|-----------|
| **>60** | **12 months OK** | Up to 900mg/day | Renal function annually |
| **30-60** | **6-12 months** | Max 300-600mg/day | Renal function 6-monthly |
| **<30** | **MAX 6 months** | Max 200mg/day, titrate slowly | Renal function 3-6 monthly |

**CRITICAL CHECKS:**
- ‚òê Dose MUST be adjusted for renal impairment
- ‚òê Start low, go slow to prevent allopurinol hypersensitivity syndrome
- ‚òê Usually start 100mg daily, increase by 100mg every 2-4 weeks

**ACTION REQUIRED:**
- Check eGFR before deciding duration
- If eGFR <60: use 6-monthly monitoring, consider 6-month prescription

**SOURCE:** BPAC gout management (2021)

---

### Colchicine

| eGFR | Prescription Duration | Dose Adjustment | Risk |
|------|----------------------|----------------|------|
| **>60** | **12 months OK** | Standard dosing (0.5mg BD) | Low risk |
| **30-60** | **MAX 6 months** | Reduce dose by 50% (0.5mg daily) | Increased toxicity |
| **<30** | **MAX 3 months** | Max 0.5mg daily or alternate days | High toxicity risk |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è Very narrow therapeutic window
- ‚ö†Ô∏è Myopathy risk if combined with statins (especially with renal impairment)
- ‚ö†Ô∏è Neuropathy with chronic use
- ‚ö†Ô∏è Toxicity symptoms: diarrhoea, nausea, muscle weakness

**ACTION REQUIRED:**
- Check eGFR before deciding duration
- If on statin + colchicine: warn about muscle pain, consider 6-month reviews
- If eGFR <60: MAX 6 months, dose reduction essential

---

### SGLT-2 Inhibitors (Empagliflozin)

| eGFR | Prescription Duration | Dose | Monitoring |
|------|----------------------|------|-----------|
| **>30** | **12 months OK** | 10-25mg daily | Annual renal function |
| **20-30** | **12 months OK** | 10mg daily max | Annual renal function |
| **<20** | **STOP** | - | - |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è **DKA risk** even with normal blood glucose - warn about symptoms
- ‚ö†Ô∏è **Fournier's gangrene** (rare but serious) - genital/perineal pain
- ‚ö†Ô∏è Genitourinary infections (UTI, thrush)
- ‚ö†Ô∏è Volume depletion risk in elderly (>75 years)

**SICK DAY RULES - MUST STOP if:**
- Acute illness, vomiting, diarrhoea, dehydration
- Use mnemonic: **SAD MANS** (Sulfonylureas, ACEi, Diuretics, Metformin, ARBs, NSAIDs, SGLT-2i)

**ACTION REQUIRED:**
- Educate about DKA symptoms (nausea, vomiting, abdominal pain, confusion)
- Sick day rules explained and documented
- Annual renal function monitoring
- Usually **12 months OK** if eGFR >20 and patient educated

**SOURCE:** BPAC diabetes management (2021); Medsafe empagliflozin guidance

---

### Sulfonylureas (Gliclazide, Glipizide)

| Situation | Prescription Duration | Monitoring | Risk |
|-----------|----------------------|-----------|------|
| **Age <70, eGFR >60** | **12 months OK** | Monitor for hypoglycaemia | Low risk |
| **Age >70 OR eGFR 30-60** | **MAX 6 months** | 6-monthly monitoring, hypo awareness | Higher hypo risk |
| **eGFR <30** | **Reduce dose, MAX 6 months** | 3-6 monthly monitoring | High hypo risk |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è **Hypoglycaemia risk** - especially elderly, renal impairment, missed meals
- ‚ö†Ô∏è Weight gain (average 2-3kg)
- ‚ö†Ô∏è Gliclazide preferred over glibenclamide (lower hypo risk)
- ‚ö†Ô∏è Glipizide better if renal impairment

**SICK DAY RULES:**
- Reduce or hold dose if fasting or acutely unwell
- Patient needs glucose monitoring if on sulfonylurea

**ACTION REQUIRED:**
- If age >70: **6 months safer** (higher hypo risk)
- If eGFR <60: **6 months**, ensure dose appropriate
- Educate about hypoglycaemia symptoms and treatment

**SOURCE:** BPAC diabetes management; NZSSD sulfonylurea guidance

---

### GLP-1 Receptor Agonists (Dulaglutide, Liraglutide)

| Type | Prescription Duration | Administration | Monitoring |
|------|----------------------|----------------|-----------|
| **Dulaglutide** | **12 months OK** | Weekly subcutaneous injection | Annual review, no routine glucose monitoring needed |
| **Liraglutide** | **12 months OK** | Daily subcutaneous injection | Annual review |

**CRITICAL CONSIDERATIONS:**
- ‚úì Injectable medication - patient must be able to self-inject
- ‚úì GI side effects common (nausea, vomiting, diarrhoea) - usually settle
- ‚ö†Ô∏è Pancreatitis risk (rare)
- ‚ö†Ô∏è Thyroid C-cell tumours in animal studies (not confirmed in humans)

**ACTION REQUIRED:**
- Patient trained in injection technique
- Usually **12 months OK** once established and tolerated
- Annual review for ongoing cardiovascular/renal benefits

**SOURCE:** BPAC diabetes management (2021)

---

### Gabapentin / Pregabalin

| eGFR | Prescription Duration | Dose Adjustment | Risk |
|------|----------------------|----------------|------|
| **>60** | **12 months OK** | Standard dosing | Low risk if appropriate indication |
| **30-60** | **6-12 months** | Dose reduction needed | Accumulation risk |
| **<30** | **MAX 6 months** | Significant dose reduction | High toxicity risk |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è **Addiction potential** - Schedule 3 controlled drug in NZ (similar to benzodiazepines)
- ‚ö†Ô∏è Sedation, dizziness, cognitive impairment (especially elderly)
- ‚ö†Ô∏è Accumulation with renal impairment
- ‚ö†Ô∏è Withdrawal syndrome if stopped suddenly
- ‚ö†Ô∏è Respiratory depression if combined with opioids

**WHEN TO USE 6 MONTHS INSTEAD OF 12:**
- Elderly patients
- eGFR <60
- Concerns about dependence
- Not clear indication (e.g., prescribed for "anxiety" or "sleep")

**ACTION REQUIRED:**
- Check eGFR before deciding duration
- If eGFR <60: dose reduction AND consider 6 months
- Document clear indication
- Annual review of ongoing need

**SOURCE:** NZ Formulary; Medsafe guidance

---

### Oral Corticosteroids (Chronic Use)

| Duration of Use | Prescription Duration | Monitoring Required |
|-----------------|----------------------|---------------------|
| **Long-term (>3 months)** | **MAX 3-6 months** | Multiple - see below |

**MONITORING REQUIRED:**
- BP, glucose, weight (every 3-6 months)
- Bone density (if >3 months use)
- Eye exam (cataracts, glaucoma annually if chronic use)
- Mood, sleep, psychosis screening

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è Multiple adverse effects: diabetes, hypertension, osteoporosis, cataracts, weight gain
- ‚ö†Ô∏è Adrenal suppression - cannot stop suddenly
- ‚ö†Ô∏è Infection risk
- ‚ö†Ô∏è Need gastroprotection if on NSAID
- ‚ö†Ô∏è Consider bone protection (calcium, vitamin D, bisphosphonate)

**ACTION REQUIRED:**
- Usually **3-6 months maximum** prescription
- Need frequent monitoring
- Document plan for weaning/stopping
- Consider specialist input for long-term use

---

### Bisphosphonates (Alendronate, Risedronate)

| eGFR | Prescription Duration | Monitoring | Notes |
|------|----------------------|-----------|-------|
| **>35** | **12 months OK** | Annual renal function | Take on empty stomach, sit upright 30min |
| **<35** | **Specialist review** | - | Contraindicated in severe renal impairment |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è **Osteonecrosis of the jaw** (rare) - dental check before starting
- ‚ö†Ô∏è **Atypical femoral fractures** (rare, long-term use >5 years)
- ‚ö†Ô∏è Oesophageal irritation - must take correctly
- ‚ö†Ô∏è Hypocalcaemia risk - ensure adequate calcium/vitamin D

**DRUG HOLIDAYS:**
- After 5 years: consider stopping in low-risk patients
- High-risk patients (fragility fractures): continue beyond 5 years

**ACTION REQUIRED:**
- Check eGFR before prescribing
- Annual dental check recommended
- If eGFR >35: **12 months OK**
- Document drug holiday consideration at 5 years

---

### Levetiracetam (Epilepsy)

| eGFR | Prescription Duration | Dose Adjustment | Monitoring |
|------|----------------------|----------------|-----------|
| **>80** | **12 months OK** | Standard | Annual review |
| **50-79** | **12 months OK** | Reduce dose | 6-12 monthly renal function |
| **30-49** | **6-12 months** | Reduce dose significantly | 6-monthly renal function |
| **<30** | **MAX 6 months** | Reduce dose significantly | 3-6 monthly renal function |

**CRITICAL:**
- Usually specialist-initiated
- Dose adjustment essential for renal impairment
- Behavioural/mood changes possible
- **12 months OK if eGFR >50** and stable

---

### Theophylline (Oral Sustained-Release)

| Situation | Prescription Duration | Monitoring |
|-----------|----------------------|-----------|
| **Stable levels, no drug interactions** | **MAX 6 months** | Levels 6-monthly, more if dose change |

**CRITICAL CONSIDERATIONS:**
- ‚ö†Ô∏è **Narrow therapeutic window** (10-20 mg/L)
- ‚ö†Ô∏è Multiple drug interactions (antibiotics, antifungals, cimetidine, etc.)
- ‚ö†Ô∏è Toxicity: nausea, vomiting, seizures, arrhythmias
- ‚ö†Ô∏è Smoking status affects levels (smokers need higher doses)

**NOT 12-MONTH DRUG:**
- Need 6-monthly level monitoring minimum
- **MAX 6 months** prescription

---

### Nitrofurantoin / Trimethoprim (Chronic UTI Prophylaxis)

| Drug | eGFR | Prescription Duration | Monitoring |
|------|------|----------------------|-----------|
| **Nitrofurantoin** | >45 | **MAX 6 months** | 6-monthly LFTs, annual renal |
| | <45 | **CONTRAINDICATED** | - |
| **Trimethoprim** | >15 | **6-12 months** | 6-monthly renal function |

**NITROFURANTOIN CRITICAL:**
- ‚ö†Ô∏è Pulmonary fibrosis risk (chronic use)
- ‚ö†Ô∏è Peripheral neuropathy
- ‚ö†Ô∏è Hepatotoxicity
- Contraindicated if eGFR <45

**TRIMETHOPRIM CRITICAL:**
- ‚ö†Ô∏è Folate antagonist
- ‚ö†Ô∏è Hyperkalaemia risk (especially if on ACEi/ARB)
- Monitor K+ in at-risk patients

---

## üî¥ RED ZONE: NOT Suitable for 12 Months

**These medications CANNOT be prescribed for 12 months - use 3 months or less**

### Controlled Drugs (üî¥ LEGAL EXCLUSION)

| Class | Maximum Duration | Examples |
|-------|-----------------|----------|
| **Class B controlled** | **1 month** | Morphine, oxycodone, fentanyl, methadone, methylphenidate, dexamphetamine |
| **Class C controlled** | **3 months** | Tramadol, codeine (prescription strength), diazepam, lorazepam, clonazepam, zopiclone, zolpidem, gabapentin, pregabalin |

**This is LAW, not clinical judgment**

**NOTE:** Gabapentin and pregabalin became Class C controlled drugs in NZ (check current status)

---

### High-Risk Medications Requiring Monitoring

| Medication | Why Unsuitable | Max Duration | Monitoring Required |
|------------|---------------|--------------|---------------------|
| **Warfarin** | INR monitoring | 1-3 months | INR varies (weekly to monthly depending on stability) |
| **Lithium** | Levels, renal, thyroid | 3 months | Levels 3-monthly (stable), renal + TFTs 3-6 monthly |
| **Digoxin** | Levels, renal, ECG | 3 months | Levels + renal 3-6 monthly, ECG annually |
| **Methotrexate** | FBC, LFTs | 3 months | FBC + LFTs monthly initially, then 2-3 monthly |
| **Azathioprine** | FBC, LFTs | 3 months | FBC + LFTs monthly initially, then 3-monthly |
| **Hydroxychloroquine** | Eye screening | 3-6 months | Annual eye exam after 5 years, FBC baseline |
| **Mycophenolate** | FBC, LFTs | 3 months | FBC weekly initially, then monthly |
| **Tacrolimus, Ciclosporin** | Levels, renal | 1-3 months | Levels frequently, renal monthly |
| **Amiodarone** | Multiple monitoring | 3 months | TFTs, LFTs 6-monthly, CXR + ECG annually |
| **Sodium valproate** | LFTs, FBC | 3 months | LFTs + FBC 6-monthly |
| **Carbamazepine** | FBC, LFTs, Na+ | 3 months | FBC + LFTs + Na+ 6-monthly |
| **Phenytoin** | Levels, FBC | 3 months | Levels as needed, FBC 6-monthly |
| **Insulin** | Regular adjustments | 3 months | Frequent glucose monitoring, dose adjustments |

**ACTION REQUIRED:**
- These medications need regular blood test monitoring
- Prescription duration should match monitoring frequency
- Usually **3 months maximum** prescription

---

### Antipsychotics (Metabolic Monitoring Required)

| Medication | Monitoring Required | Max Duration | Risk Level |
|------------|---------------------|--------------|------------|
| **Olanzapine, Clozapine** | Weight, glucose, lipids | **3 months** | Highest metabolic risk |
| **Quetiapine, Risperidone** | Weight, glucose, lipids | **3 months** | Medium metabolic risk |
| **Haloperidol, Chlorpromazine** | Weight, glucose | **3-6 months** | Lower metabolic risk |

**Monitoring schedule:**
- **Baseline:** Weight/BMI, waist circumference, glucose, lipids, BP
- **3 months:** Repeat all above
- **Then annually** if continued: Weight/BMI, glucose, lipids

**Why unsuitable for 12 months:**
- High risk of metabolic syndrome (weight gain, diabetes, dyslipidaemia)
- Olanzapine/clozapine: Average weight gain 5-6kg over 48 weeks
- Need regular weight and metabolic monitoring
- Movement disorder screening (tardive dyskinesia)

**NOTE:** Usually specialist-initiated; GPs typically provide repeat prescriptions  
**SOURCE:** BPAC metabolic monitoring guidance (2007, 2011)

**ACTION REQUIRED:**
- Baseline and 3-monthly metabolic monitoring
- Usually **3 months maximum** prescription

---

### NSAIDs (Chronic Use)

**NOTE:** NSAIDs are in AMBER zone with restrictions - see AMBER section for details
- If chronic use needed: MAX 6-12 months depending on situation
- If "triple whammy": MAX 3 months (RED zone)

---

## Special Situations & Clinical Pearls

### "Triple Whammy" Warning (ACEi/ARB + Diuretic + NSAID)
- ‚ö†Ô∏è If patient on ACEi/ARB + diuretic:
  - **Warn about over-the-counter NSAIDs**
  - More frequent renal monitoring needed if NSAID required
  - Consider 6 months instead of 12 months

### Polypharmacy (‚â•5 medications)
- ‚ö†Ô∏è Consider **6 months** instead of 12 months for:
  - Better medication reconciliation
  - Earlier detection of adverse effects
  - More frequent clinical review

### Age >75 Years
- ‚ö†Ô∏è Physiological decline in renal function even if eGFR normal
- ‚ö†Ô∏è For renally excreted drugs (DOACs, metformin, ACEi/ARBs):
  - Consider 6-monthly reviews
  - More frequent renal function monitoring

### Unstable Housing / Transport Barriers
- ‚úì 12-month prescriptions may IMPROVE access for these patients
- ‚úì Reduces cost and transport burden
- ‚úì BUT ensure they can attend annual review (offer home visits if needed)

### MƒÅori Patients
- ‚úì Consider barriers to access: will 12 months help or hinder?
- ‚úì Proactive outreach for annual review
- ‚úì Discuss what works best for patient and whƒÅnau

---

